Current Edition

Bristol Myers Squibb

In newly diagnosed stomach cancer, 2 Opdivo-Yervoy flops show immunotherapy alone might not be the answer

Bristol Myers Squibb boasts a historic go-ahead for Opdivo plus chemotherapy as the first immunotherapy regimen for previously untreated stomach cancer. But the PD-1 inhibitor …

Continue Reading →

ESMO: Bristol Myers’ Opdivo-Yervoy, Pfizer-Merck KGaA’s Bavencio hit walls in head and neck cancer

Suffering two separate clinical trial blows, Bristol Myers Squibb and a collaboration between Merck KGaA and Pfizer learned the hard way that head and neck …

Continue Reading →